ADJUSTING A CANCER MORTALITY-PREDICTION MODEL FOR DISEASE STATUS-RELATED ELIGIBILITY CRITERIA



Substituted pteridinones, pyrimidines, pyrrolopyrimidines, and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitors: Pharmacophore modeling data

The RSK2 kinase is a downstream effector of the Ras/Raf/MEK/ERK pathway that is aberrantly active in a range of cancer types and has been recognized an anticancer target.The inhibition of RSK2 kinase activity would disrupt multiple pro-cancer processes; however, there are few RSK2 inhibitors.The Body Spray data have been obtained for a series of pt

read more